<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02609269</url>
  </required_header>
  <id_info>
    <org_study_id>GRD001</org_study_id>
    <nct_id>NCT02609269</nct_id>
  </id_info>
  <brief_title>Decipher Genomics Resource Information Database</brief_title>
  <acronym>GRID®</acronym>
  <official_title>Prospective Expression Analysis Using The Decipher Genomics Resource Information Database (GRID)® and Data Sharing Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GenomeDx Biosciences Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GenomeDx Biosciences Corp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To prospectively evaluate the utility of genomic expression data as a tool to better
      characterize the tumors of individual patients, and to understand how genomic information
      from individual patients undergoing routine clinical testing can be used in population-level
      analysis to improve treatment and outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational study involving the release of genome-wide expression data allowing
      participating institutions to pair these data with clinical treatment and outcome data for
      patients in whom Decipher testing was performed. Through these collaborations, the GRID
      database population will be used to characterize the genomics of cancer and discover new gene
      expression signatures that may be useful for expanding the current understanding of the
      biology of the disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Link complete genomic RNA expression array data generated from Decipher testing with clinical data for patients who consent to participate.</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Role of genomic expression data in the biology of certain cancers</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Decipher GRID Patients</arm_group_label>
    <description>Patients who have been tested with any of the Decipher suite of genomic solutions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Decipher Prostate Cancer Classifier</intervention_name>
    <description>The Decipher Prostate Cancer Classifier (Decipher Test) is a genomic test that predicts the probability of high-grade disease, metastasis and prostate cancer specific mortality for men with prostate cancer and is commercially available through GenomeDx Biosciences' CLIA &amp; CAP certified laboratory in San Diego, CA</description>
    <arm_group_label>Decipher GRID Patients</arm_group_label>
    <other_name>Decipher Biopsy, Decipher Post-Op, Decipher Test</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Decipher Genomics Resource Information Database (GRID)</intervention_name>
    <description>The Decipher GRID (GRID) is the world's largest research use only (RUO), clinically annotated urologic cancer genomic expression database, built up over 8 years of US and international research conducted using the Decipher® (Decipher) test platform. The GRID currently consists of genomic data comprised of 1.4M data points per patient from more than 20,000 prostate and bladder cancer patients, including those from published retrospective clinical studies that have been annotated with comprehensive treatment and outcomes data. It is anticipated that the GRID will also contain data from several other types of cancer in the future.</description>
    <arm_group_label>Decipher GRID Patients</arm_group_label>
    <other_name>Decipher GRID</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing Decipher testing in the clinical setting. It is understood that the
        Decipher test results may be used as a part of normal clinical care. Any patient meeting
        the following criteria who has been tested with Decipher can participate in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Decipher Post-Op Clinical Indications

          -  Patient must have achieved initial PSA nadir (defined as undetectable PSA of

             ≤0.1 ng/mL) within 4-6 weeks, and

          -  Pathological stage T2 disease with a positive surgical margin, or

          -  Pathological stage T3 disease (e.g., extraprostatic extension, seminal vesicle
             invasion, bladder neck invasion), or

          -  High Preoperative PSA (e.g., PSA ≥20 ng/mL), or

          -  High Gleason grade disease (e.g., Gleason 7 to 10 or Tertiary Gleason pattern 5), or

          -  Perineural, lymphovascular invasion, or

          -  Lymph node involvement, or

          -  Rising PSA or Biochemical Recurrence

        Decipher Biopsy Clinical Indications

        • Any patient diagnosed with localized prostate cancer and assessed as being very low, low,
        intermediate or high risk by NCCN guidelines:

          1. Very low risk: T1c, Gleason score ≤ 6, PSA &lt; 10ng/mL, fewer than 3 prostate biopsy
             cores positive,

               -  50% cancer in any core, PSA density &lt;0.15 ng/mL/g

          2. Low risk: T1-T2a, Gleason score ≤ 6, PSA &lt; 10ng/mL

          3. Intermediate risk: T2b-T2c, Gleason score 7, or PSA 10-20 ng/mL

          4. High risk: T3a, or Gleason score 8-10, or PSA &gt; 20 ng/mL

        Exclusion Criteria:

          1. Diagnosed with metastatic disease (M1)

          2. Metastatic Disease (M+) prior to surgery

          3. For salvage setting patients: Metastatic Disease (M+) at PSA rise

          4. Received any neo-adjuvant prostate cancer treatment before radical prostatectomy

          5. Required patient clinical data is not available for evaluation of eligibility criteria

          6. Any other medical condition that the treating physician,study investigators or
             designee determines should exclude the subject from the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elai Davicioni, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>President &amp; Chief Scientific Officer, GenomeDx Biosciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tim Triche, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>aboratory Medical Director and Chairman, GenomeDx Biosciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jill Collins, PhD</last_name>
    <phone>1-858-322-6161</phone>
    <email>jill.collins@genomedx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Desert Medical Imaging LLC</name>
      <address>
        <city>Indian Wells</city>
        <state>California</state>
        <zip>92210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernadette Greenwood, BS, PG cert.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyung L. Kim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Carroll, MD, MPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanoj Punnen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kosj Yamoah, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward M Schaeffer, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Ross, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber/Brigham and Women's Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul L. Nguyen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Urology</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirk J Wojno, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Medical College at Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam P. Dicker, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.genomedx.com</url>
    <description>Website for GenomeDx Biosciences (study sponsor)</description>
  </link>
  <reference>
    <citation>Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP, Crisan A, Erho N, Vergara IA, Lam LL, Carlson R, Thompson DJ, Haddad Z, Zimmermann B, Sierocinski T, Triche TJ, Kollmeyer T, Ballman KV, Black PC, Klee GG, Jenkins RB. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol. 2013 Dec;190(6):2047-53. doi: 10.1016/j.juro.2013.06.017. Epub 2013 Jun 11.</citation>
    <PMID>23770138</PMID>
  </reference>
  <reference>
    <citation>Ross AE, Johnson MH, Yousefi K, Davicioni E, Netto GJ, Marchionni L, Fedor HL, Glavaris S, Choeurng V, Buerki C, Erho N, Lam LL, Humphreys EB, Faraj S, Bezerra SM, Han M, Partin AW, Trock BJ, Schaeffer EM. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. Eur Urol. 2016 Jan;69(1):157-65. doi: 10.1016/j.eururo.2015.05.042. Epub 2015 Jun 6.</citation>
    <PMID>26058959</PMID>
  </reference>
  <reference>
    <citation>Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol. 2015 Feb;67(2):326-33. doi: 10.1016/j.eururo.2014.05.039. Epub 2014 Jul 2.</citation>
    <PMID>24998118</PMID>
  </reference>
  <reference>
    <citation>Den RB, Yousefi K, Trabulsi EJ, Abdollah F, Choeurng V, Feng FY, Dicker AP, Lallas CD, Gomella LG, Davicioni E, Karnes RJ. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol. 2015 Mar 10;33(8):944-51. doi: 10.1200/JCO.2014.59.0026. Epub 2015 Feb 9. Erratum in: J Clin Oncol. 2015 Apr 20;33(12):1416.</citation>
    <PMID>25667284</PMID>
  </reference>
  <reference>
    <citation>Den RB, Feng FY, Showalter TN, Mishra MV, Trabulsi EJ, Lallas CD, Gomella LG, Kelly WK, Birbe RC, McCue PA, Ghadessi M, Yousefi K, Davicioni E, Knudsen KE, Dicker AP. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1038-46. doi: 10.1016/j.ijrobp.2014.04.052. Epub 2014 Jul 8.</citation>
    <PMID>25035207</PMID>
  </reference>
  <reference>
    <citation>Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, Bergstralh EJ, Kollmeyer T, Fink S, Haddad Z, Zimmermann B, Sierocinski T, Ballman KV, Triche TJ, Black PC, Karnes RJ, Klee G, Davicioni E, Jenkins RB. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One. 2013 Jun 24;8(6):e66855. doi: 10.1371/journal.pone.0066855. Print 2013.</citation>
    <PMID>23826159</PMID>
  </reference>
  <reference>
    <citation>Choeurng, V. et al., Recalibration of Genomic Risk Prediction Models in Prostate Cancer to Improve Individual-Level Predictions. JSM 2015 Abstract.</citation>
  </reference>
  <reference>
    <citation>Den, R. et al., Validation of a Genomic Classifier for Prediction of Metastasis following Postoperative Salvage Radiation Therapy. J Clin Oncol 33, 2015 (suppl; abstr 5016).</citation>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2015</study_first_submitted>
  <study_first_submitted_qc>November 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

